Poster on MANATEE: Roche and Genentech clinical study of GYM329 (RO7204239) in combination with risdiplam treatment in children with SMA
MANATEE is a global, Phase 2/3 study that will assess GYM329 in combination with risdiplam in ambulant (able to walk independently) children with SMA aged 2-10 years. Children who have been previously treated with either risdiplam, nusinersen or onasemnogene abeparvovec are eligible, as well as those who have not received treatment before. Other eligibility criteria exist.
For more information, please see below to consult the poster.